





17TH IASLC WORLD CONFERENCE **ON LUNG CANCER**

DECEMBER 4-7, 2016 VIENNA, AUSTRIA

First Announcement

IMPORTANT DATES

Online Registration **FEBRUARY 22, 2016** & Housing Opens **Abstract Submission FEBRUARY 22, 2016** Opens **Abstract Submission JULY 15, 2016** Deadline **Author Notifications SEPTEMBER 14, 2016 Early Registration SEPTEMBER 23, 2016** Deadline

Late-Breaking Abstract **Submission Deadline**

Regular Registration Deadline

OCTOBER 21, 2016

OCTOBER 15, 2016







FOLLOW US ON FACEBOOK



Welcome Message



CONFERENCE PRESIDENT:

Robert Pirker, MDDepartment of Medicine I
Medical University of Vienna

Währinger Gürtel 18-20 1090 Vienna Austria

Email: robert.pirker@ meduniwien.ac.at Phone: +4314040044220

or 49530

Dear Doctors, Dear Colleagues, Dear Friends,

The 17th IASLC World Conference on Lung Cancer of the International Association for the Study of Lung Cancer (IASLC) will take place from December 4 to 7, 2016, in Vienna, Austria. The science of lung cancer is advancing so rapidly that the IASLC decided to hold the World Conferences annually. The WCLC in Vienna will be the first of the annual Conferences, following the World Conference in Denver in 2015.

On behalf of IASLC as well as the members of the Organizing and Program Committees, I cordially invite you to attend the World Conference 2016 in Vienna.

The Conference motto "WCLC 2016 Together against Lung Cancer" captures the collaborative spirit of the Conference which will be a scientific and educational event covering three major topics:

Active Prevention, Accurate Diagnosis, Advanced Care.

Medical doctors, scientists, nurses, health professionals, government officials, partners from the industry, health advocacy groups and patients will come together in order to obtain and exchange information on both state-of-the-art and advances in the management of lung cancer and other thoracic malignancies, considering both global and regional aspects.

I ask you to submit your latest research results for presentation. You are also welcome to suggest any topic, activity or scientific program you would like to see covered during the World Conference. Your active contribution will be crucial to the success of the World Conference and its impact on our global mission to prevent, diagnose and treat lung cancer and other thoracic malignancies. Together, we will become a stronger voice and global force and will succeed in decreasing the world-wide burden of lung cancer.

I hope that, despite an intense Conference program, you also will be able to get some glimpses of Vienna, the capital of Austria. Vienna is a cosmopolitan and modern city and host to many international organizations including the United Nations. Vienna is also a city rich in history, architecture and culture. I hope that you will be inspired by the Viennese art of living.

I am looking forward to personally welcoming you to the Vienna World Conference from all parts of the world.

Yours sincerely,

Robert Pirker, MD

WCLC 2016 Conference President

CONFERENCE PRESIDENT

Robert Pirker, Austria

REGIONAL ORGANIZING COMMITTEE

Otto Chris Burghuber, Austria

Martin Filipits, Austria

Christian Herold, Austria

Wolfgang Hilbe, Austria

Walter Klepetko, Austria

Meinhard Kneussl, Austria

Michael Rolf Müller, Austria

Gyula Ostoros, Hungary

Lubos Petruzelka, Czech Republic

Robert Pirker, Austria

Helmut Popper, Austria

Richard Pötter, Austria

Herbert Watzke, Austria

Christoph Zielinski, Austria

Sabine Zöchbauer-Müller, Austria

CORE PROGRAM COMMITTEE

Robert Pirker, Austria (Chair)

Hisao Asamura, Japan

Michael Boyer, Australia

Karin Dieckmann, Austria

Wilfried Eberhardt, Germany

Martin Filipits, Austria

Kwun Fong, Australia

Fred R Hirsch, USA

Rudolf M Huber, Germany

Walter Klepetko, Austria

Gabor Kovacs, Hungary

Christian Manegold, Germany

Gyula Ostoros, Hungary

Helmut Popper, Austria

Helmut Prosch, Austria

Herbert Watzke, Austria

Caicun Zhou, China

Christoph Zielinski, Austria

Sabine Zöchbauer-Müller, Austria



CONFERENCE COMMITTEES

PROGRAM COMMITTEES

EPIDEMIOLOGY/ PRIMARY PREVENTION / TOBACCO CONTROL AND CESSATION

Gabor Kovacs, Hungary (Chair) Manfred Neuberger, Austria (Co-Chair) Nazmi Bilir, Turkey Mike Cummings, USA Mike Daube, Australia Carolyn Dresler, USA Florin Mihaltan, Romania Martina Pötschke-Langer, Germany Alexander Prokhorov, USA Surenda S Shastri, India Tomotaka Sobue, Japan Nise Yamaguchi, Brazil Zarihah Zain, Malaysia Xiuyi Zhi, China

BIOLOGY

Martin Filipits, Austria (Chair)
Roman Thomas, Germany
(Co-Chair)
David Carbone, USA
Balasz Dome, Hungary
Ramaswamy Govindan, USA
John Minna, USA
Tetsuya Mitsudomi, Japan
Leonhard Müllauer, Austria
Jacek Niklinski, Poland
Kazuto Nishio, Japan
Rafael Rosell, Spain
Benjamin Solomon, Australia
Charles Swanton, UK

PATHOLOGY

Helmut Popper, Austria Keith Kerr, UK (Co-Chair) Vera Capelozzi, Brazil Wendy Cooper, Australia Gerhard Dekan, Austria Adi F Gazdar, USA Fred R Hirsch, USA Andrew Nicholson, UK Masayuki Noguchi, Japan Wlodzimierz Olszewski, Poland Iver Petersen, Germany Ales Ryska, Czech Republic Philipp Schnabel, Germany lozsef Timar, Hungary William Travis, USA Yasushi Yatabe, Japan

RADIOLOGY/STAGING/ SCREENING

Helmut Prosch, Austria (Chair)
Peter Goldstraw, UK
(Co-Chair)
Hisao Asamura, Japan
John Field, UK
Jhingook Kim, South Korea
Pierre Massion, USA
Michael Rolf Müller, Austria
Edward F Patz, USA
Ramon Rami-Porta, Spain
Stefan Schönberg, Germany
Rob J van Klaveren,
Netherlands
Jiri Votruba, Czech Republic
Ignacio Wistuba, USA

PULMONOLOGY

Gyula Ostoros, Hungary (Chair) Rudolf M Huber, Germany (Co-Chair) Eric Edell, USA Salih Emri, Turkey Kwun Fong, Australia Felix Herth, Germany Vitezslav Kolek, Czech Republic Anne-Pascale Meert, Belgium Yoichi Nakanishi, Japan Nevena Secen, Serbia Ruxandra Ulmeanu, Romania Konstantinos Zarogoulidis, Greece

EARLY STAGE NSCLC

Michael Rolf Müller, Austria (Chair) Glenwood Goss, Canada (Co-Chair) Frank Griesinger, Germany Norihiko Ikeda, Japan Miroslaw Kozlowski, Poland Thierry Le Chevalier, France Bernward Passlick, Germany Lubos Petruzelka, Czech Republic Giorgio Scagliotti, Italy Suresh Senan, Netherlands Heather Wakelee, USA

LOCALLY ADVANCED NSCLC

Wilfried Eberhardt, Germany (Chair)
Francoise Mornex, France (Co-Chair)
Michael Boyer, Australia
Rafal Dziadziuszko, Poland
Hans Hoffmann, Germany
Kaoru Kubota, Japan
Keunchil Park, South Korea
Georg Stamatis, Germany
Everett Vokes, USA
Walter Weder, Switzerland
Milada Zemanova,
Czech Republic

ADVANCED NSCLC

Robert Pirker, Austria (Chair) David R. Gandara, USA (Co-Chair) Tanja Cufer, Slovenia Koichi Goto, Japan Cesare Gridelli, Italy Jaroslaw Kuzdzal, Poland Rogerio Lilenbaum, USA Reza Malayeri, Iran Christian Manegold, Germany Sergey Orloff, Russia Lubos Petruzelka, Czech Republic Elisabeth Quoix, France Eduardo Richardet, Argentina Martin Schuler, Germany Takashi Seto, Japan Sumitra Thongprasert, Thailand Li Zhang, China

SCLC/ NEUROENDOCRINE TUMORS

Sabine Zöchbauer-Müller, Austria (Chair) Jens Benn Sorensen, Denmark (Co-Chair) Andrea Ardizzoni, Italy Hideo Kunitoh, Japan Seppo Langer, Denmark Primo Lara, USA Cecile Le Pechoux, France Eric Lim, UK Nevin Murray, Canada Pieter E Postmus, Netherlands Jean Louis Pujol, France Berend Jan Slotman, Netherlands

MESOTHELIOMA/ THYMIC MALIGNANCIES/ ESOPHAGEAL CANCER/ OTHER THORACIC MALIGNANCIES

Walter Weder, Switzerland (Chair) Mir Alireza Hoda, Austria (Co-Chair) Paul Baas, Netherlands Frank Detterbeck, USA Dean Fennell, UK Seiki Hasegawa, Japan Muzaffer Metintas, Turkey Takashi Nakano, Japan Meinoshin Okumura, Japan Harvey Pass, USA Thomas Rice, USA Arnaud Scherpereel, France Jan van Meerbeeck, Belgium Nico van Zandwijk, Australia

SURGERY

Walter Klepetko, Austria (Chair) Dominique Grunenwald, France (Co-Chair) Alessandro Brunelli, UK Saulius Cicenas, Lithuania Young Tae Kim, South Korea Anthony Linegar, South Africa Oleg Pikin, Russia CS Pramesh, India Kenji Suzuki, Japan Alper Toker, Turkey . Masahiro Tsuboi, Japan Eric Vallieres, USA Shun-ichi Watanabe, Japan Yi Long Wu, China

RADIOTHERAPY

Karin Dieckmann, Austria (Chair) Jacek Jassem, Poland (Co-Chair) David Ball, Australia Michael Baumann, Germany Hak Choy, USA Laurie Gaspar, USA Satoshi Ishikura, Japan Antonio Juretic, Croatia Rolf Lewensohn, Sweden Yuko Nakayama, Japan Richard Pötter, Austria Umberto Ricardi, Italy Deniz Yalman, Turkey

CHEMOTHERAPY/ TARGETED THERAPY

Robert Pirker, Austria (Chair) Rolf Stahel, Switzerland (Co-Chair) Oscar Arrieta, Mexiko Filippo de Marinis, Italy Oliver Gautschi, Switzerland Akihiko Gemma, Japan Roy Herbst, USA Pasi A Janne, USA Julian Molina, USA Kazuhiko Nakagawa, Japan Kenneth O'Byrne, Australia Zhou Qing, China Lu Shun, China Branimir Sikic, USA lean Charles Soria, France Kostas Syrigos, Greece Joachim von Pawel, Germany Jürgen Wolf, Germany James Chih-Hsin Yang, Taiwan Caicun Zhou, China

IMMUNOLOGY AND IMMUNOTHERAPY

Christoph Zielinski, Austria (Chair) Charles Butts, Canada (Co-Chair) Maya Gottfried, Israel Raffit Hassan, USA Tony Mok, China Marcin Moniuszko, Poland Anna Nowak, Australia Martin Reck, Germany David Spigel, USA Johan Vansteenkiste, Belgium

SUPPORTIVE & PALLIATIVE CARE/ETHICS

Herbert Watzke, Austria (Chair) Jean Klastersky, Belgium (Co-Chair) Gouri Shankar Bhattacharyya, India Nathan Cherny, Israel Jeffrey Crawford, USA Lutz Freitag, Germany Richard Lim, Malaysia Jennifer Temel, USA Arschang Valipour, Austria

TRIAL DESIGN / STATISTICS

Lothar Pilz, Germany (Chair) Stefan Michiels, France (Co-Chair) Ladislav Dusek, Czech Republic Daniel Shao-Weng Tan, Singapore Yu Shyr, USA Kurt Ulm, Germany

REGIONAL ASPECTS / HEALTH POLICY / PUBLIC HEALTH

Christoph Zielinski, Austria (Chair) Nagahiro Saijo, Japan (Co-Chair) Carlos Barrios, Brazil Digambar Behera, India Paul A Bunn, Jr, USA Tudor Ciuleanu, Romania Jaime de la Garza, Mexico Rabab Gaafar, Egypt Vera Gorbunova, UK Gilberto de Lima Lopes, Brazil Tatiana Vidaurre-Rojas, Peru

SCIENTIFIC CO-OPERATION / CO-OPERATIVE GROUPS

Thomas Brodowicz, Austria (Chair)
Clarissa Mathias, Brazil (Co-Chair)
Benjamin Besse, France
Haruyuki Fukuda, Japan
Jin Soo Lee, South Korea
Yuichiro Ohe, Japan
Solange Peters, Switzerland
Suresh Ramalingam, USA
Tora Shibata, Japan
Michael Thomas, Germany
Carlos Vallejos Sologuren,
Peru
Ufuk Yilmaz, Turkey

EDUCATION/PUBLICATION / CAREER DEVELOPMENT

Alex Adjei, USA (Chair)
Peter Berzinec, Slovakia
(Co-Chair)
Jean Yves Douillard, France
Ednin Hamzah, Malaysia
Barbara Melosky, Canada
Judit Moldvay, Hungary
Masayuki Noguchi, Japan
Silvia Novello, Italy
Gunta Purkalne, Latvia
Carlos Silva, Argentina
Navneet Singh, India
Ross Soo, Singapore
Irina Strambu, Romania

YOUNG INVESTIGATORS

Maximilian Hochmair, Austria (Chair)
Amanda Tufman, Germany (Co-Chair)
Luigi De Petris, Sweden
Georgia Hardavella, UK
Miroslaw Kozlowski, Poland
Prasanta R. Mohapatra, India
Fedor Moiseenko, Russia
Milla Petrova, Bulgaria
Mirjana Rajer, Slovenia
Thanyanan Reugwetwattana,
Thailand
Matthias Scheffler, Germany
Bojan Zaric, Serbia

NURSES

Liz Darlison, UK Peter Koren, Slovenia Harald Titzer, Austria

PATIENTS SUPPORT AND ADVOCACY GROUP

Ingeborg Beunders, Austria (Chair) Stefania Vallone, Italy (Co-Chair) Bonnie Addario, USA Franz Buchberger, Austria Szymon Chrostowski, Poland Sandra Karabatic, Croatia Pawel Moszumanski, Poland Christina Ny, Malaysia Shani Shilo, Israel Andreja Skufca-Smrdel, Slovenia

INTERNATIONAL SCIENCE ADVISORY COMMITTEE

Myung-Ju Ahn, South Korea Kurt Aigner, Austria Kathy Albain, USA Gerhad Ambrosch, Austria Athanassios Argiris, USA Madeleine Arns, Austria Jair Bar, Israel Fabrice Barlesi, France Chandra P Belani, USA Walter Berger, Austria Thierry Berghmans, Belgium Daniel C Betticher, Switzerland Fiona H Blackhall, UK Philip Bonomi, USA Elisabeth Brambilla, France Odd Terje Brustugun, Norway lacques Cadranel, France Priscilla Caguioa, Philippines Ross Camidge, USA Frederico Cappuzzo, Italy Andres Felipe Cardona Zorrilla, Colombia Desmond Carney, Ireland Christos Chouaid, France Hak Choy, USA Tsai Chun-Ming, Taiwan Lucio Crino, Italy Walter I Curran, USA Paul de Leyn, Belgium Mircea Dediu, Romania Karl-Matthias Deppermann, Dirk DeRuysscher, Belgium Hendrik Dienemann, Germany Steven Dubinett, USA Simon Eckman, Sweden Josef Eckmayr, Austria Mark Edelman, USA Lawrence Einhorn, USA David Ettinger, USA Corinne Faivre-Finn, UK Enriqueta Felip, Spain Panos Fidias, USA Berthold Fischer, Germany Pierre Fournel, France Wilbur Franklin, USA Martin Früh, Switzerland Christian Geltner, Austria Vassilis Georgoulias, Greece Giuseppe Giaccone, USA Robert Godal, Slovakia Richard Gralla, USA Richard Greil, Austria Alexandru Grigorescu, Romania Bjorn Gronberg, Norway Nasser Hanna, USA Libor Havel, Czech Republic Vera Hirsh, Canada Mohamed Ibrahim A Wahid, Malaysia David Jablons, USA Antti Jekunen, Finland James Jett, USA Bruce Johnson, USA David Johnson, USA

Dragana Jovanovic, Serbia

Dimitar Kalev, Bulgaria Ahmad Kamal bin Mohamed, Malaysia Peter Kasan, Slovakia Terufumi Kato, Japan Karen Kelly, USA Izidor Kern, Slovenia Klaus Kirchbacher, Austria Rainer Kolb, Austria Paris Kosmidis, Greece Viljem Kovac, Slovenia Krassimir Koynov, Bulgaria Mark Kris, USA Maciej Krzakowski, Poland Johan Kurnianda, Indonesia Gyoergy Lang, Austria Corey Langer, USA Natasha Leighl, Canada Zhang Li, China Bo Lu, USA Thomas Lynch, USA Jorge Madrid, Chile Talha Mahmud, Pakistan Aaron Mansfield, USA Antonio Marchetti, Italy Alexander Marx, Germany Mohammadreza Masjedi, Iran Peter Meldgaard, Denmark Anders Mellemgaard, Denmark Patrick Micke, Sweden Andrea Mohn-Staudner, Denis Moro-Sibilot, France James L Mulshine, USA Bruno Niederle, Germany Eeva-Maija Niminen, Finland Jan Nyman, Sweden Mary O'Brien, UK Georg Pall, Austria William Pao, USA Vali Papadimitrakopoulou, **USA** Ugo Pastorino, Italy Nick Pavlakis, Australia Luis Paz-Ares, Spain Tobias Peikert, USA Nir Peled, Israel Roman Perez-Soler, USA Branislav Perin, Serbia Maurice Perol, France David Planchard, France Christoph Pöttgen, Germany Luis R Raez, USA Rodryg Ramlau, Poland Dennis Ramon M.Tudtud, **Philippines** Niels Reinmuth, Germany Sacha Rothschild, Switzerland Charles Rudin, USA Ravi Salgia, USA Miroslav Samarzija, Croatia Hellmut Samonigg, Austria Joan Schiller, USA

B Shadmehr, Iran Frances A Shepherd, Canada Maria Sibilia, Austria George Simon, USA Jana Skrickova, Czech Republic Egbert Smit, Netherlands Mark Socinski, USA Pierre-Jean Souquet, France David Stewart, Canada Leopold Stiebellehner, Austria Philipp Ströbel, Germany Michael Studnicka, Austria Martin Stuschke, Germany Noorwati Sutandyo, Indonesia Shahrokh Taghavi, Austria Nick Thatcher, UK Erik Thunnissen, Netherlands Ming Tsao, Canada Pál Vadász, Hungary Paul van Houtte, Belgium Paul van Schil, Belgium Marileila Varella-Garcia, USA Antonio Villalon, Philippines Anne Warth, Germany Thomas Wehler, Germany Virginie Westeel, France lia Wia, China Rainer Wiewrodt, Germany Antoinette Wozniak, USA Faruk Zorlu, Turkey

(As of January 29, 2016)

Wolfgang Schütte, Germany

Jean-Paul Sculier, Belgium

Monika Serke, Germany

Martin Sebastian, Germany

Scientific Program & Accreditation

Goals

The World Conference is an educational and scientific event which, due to its multidisciplinary nature, will cover all aspects of the management of lung cancers, mesothelioma, thymic and other thoracic malignancies.

Participants will learn about tobacco control and smoking cessation programs and how to implement them in their daily practice. Participants will update their knowledge on early detection and screening.

The Conference will provide lectures on accurate diagnosis including molecular diagnosis, state-of-the-art treatment of thoracic malignancies, and recent diagnostic and therapeutic advances. Participants will learn about palliative care and its implementation in daily practice.

Participants will be informed about the possibilities for continuous medical education. They will learn about clinical trial designs and how to become successful investigators of co-operative research groups. The Conference will also allow participants to be better informed about patient support and advocacy groups.

Overall, the participants of the World Conference will benefit with regard to best clinical practice in the area of lung cancer and other thoracic malignancies.

• State-of-the-art management

- New developments in surgery
- VATS
- Stereotactic radiotherapy
- Adjuvant chemotherapy and targeted therapies
- Follow-up of patients

CME Accreditation

This activity is planned for AMA PRA Category 1 Credit(s)™

EACCME accreditation (Europe)

American Medical Association (AMA) credits are recognized by EACCME. To convert AMA PRA category 1 credit(s)™ to EACCME credit, contact the EACCME.

Please visit the Conference website at www.iaslc.org for further information.

Official Language

The official language of the 17th IASLC World Conference on Lung Cancer is English.

TOPICS

Epidemiology and Prevention

- Global and regional epidemiological trends
- Tobacco control, smoking cessation programs and strategies for improvement
- Reduction of environmental exposure
- Chemoprevention

Biology and Pathology

- Signal transduction pathways
- Gene signatures
- Driver mutations
- Proteomics
- Epigenetics
- Precursor lesions of lung cancer
- Histopathological and molecular classification of lung cancer
- Primary tumors versus metastases
- Adequate tissue sampling
- Molecular analysis techniques
- Molecular biomarkers
- Immune surveillance
- Mouse models of lung cancer

Early Detection and Diagnosis

- Current status, challenges and perspectives of screening
- Molecular lung cancer risk assessment
- Advances in bronchoscopy and imaging
- Minimally invasive and surgical staging
- 8th TNM classification and its clinical implications
- Management of indeterminate pulmonary nodules
- Circulating tumor cells

Early Stage NSCLC

Locally Advanced NSCLC

- State-of-the-art management
- The role of surgery
- Perspectives of radiotherapy
- Advances in systemic therapies

Advanced NSCLC

- State-of-the-art therapy
- Management of oligometastatic disease
- Treatment of elderly patients and patients with poor performance status

Small Cell Lung Cancer

- State-of-the-art therapy
- Optimal integration of radiotherapy
- Novel drugs

Mesotheliomas, Thymic Malignancies and Other Thoracic Malignancies

- Pathological subtypes of mesotheliomas
- Classification of thymic malignancies
- State-of the-art management
- Molecular targets
- Novel drugs
- Immune therapy

Surgery

- Novel developments in resection techniques
- VATS
- Robotic surgery
- The importance of patient volume

Radiotherapy

- Advances in radiotherapy planning and techniques
- Stereotactic radiotherapy
- Proton therapy

Chemotherapy, Targeted Therapies and Immunotherapy

- Preclinical models
- Novel cytotoxic and targeted drugs
- Resistance mechanisms
- Biomarkers and pharmacogenomic approaches
- Immune check-point inhibitors
- Efficacy assessment and management of side effects
- Liquid biopsies

Session Overview

Palliative Care and Ethics

- Comprehensive management of tumor symptoms
- Tumor cachexia
- Infection
- The impact of hematopoietic growth factors and biphosphonates
- Nutrition
- Psychosocial support
- Palliative care units, mobile care teams and hospices
- End-of-life care

Clinical Trial Design and Statistics

- Recent developments in trial designs including master protocols
- Early efficacy assessment
- The relevance of clinical endpoints
- The importance of validation
- Bioinformatics
- Statistics for clinicians

Education, Scientific Co-Operation and Research Groups

- Education of doctors, health professionals and the public on the global epidemic of lung cancer and other smoking-related cancers
- The role of multidisciplinary tumor boards
- Update on ongoing phase III trials
- Strategies for enhanced co-operation of co-operative groups
- Co-operation with industry
- Regulatory issues

Regional Aspects, Health Policy and Public Health

- Delivery of health measures
- Cost effectiveness and its relevance
- Dealing with increasing economic pressure
- Minimal requirements for diagnosis and care
- Measures for increased access to modern imaging techniques
- Strategies for earlier diagnosis in low-income countries
- Co-operation in the field of primary prevention
- Stronger global voice for prevention strategies and for patients with thoracic cancers
- Co-operation with scientific organizations, governments and non-governmental organizations
- The impact of patient support and advocacy groups
- The role of medical journals and public media

Educational Sessions

These sessions offer multidisciplinary exploration of focused topics related to thoracic oncology. Particular care will be taken to ensure that these sessions are integrated in terms of such issues as surgical, radiation, and medical oncology; symptom management; health services research; global perspectives; and pathology, as appropriate.

Highlights of the Day Sessions

In these sessions, experts in the field will summarize the essence of selected abstracts of clinical/translational research presented on the previous day.

Interactive Sessions

These sessions invite active participation of the audience. Topics will be case presentations, scientific advances and controversial topics.

Meet the Expert Sessions (MTE – Ticketed Sessions)

These sessions provide open discussion between recognized experts and session attendees, with an opportunity for attendees to interact personally with the experts.

(Not included in registration, additional fees apply. Limited capacity.)

Mini Symposia Sessions

In these sessions, reports on the latest scientific results, controversial issues, and emerging concepts will be presented. Experts in the field place the studies in the appropriate context based on the strength of the evidence and critically discuss the conclusions in terms of their applicability to clinical practice.

Plenary Sessions and Presidential Symposium

In Plenary sessions, several lectures which are of particular interest, importance, and relevance to attendees, will be presented. Top-scoring abstracts selected by the Scientific Committee will be presented in the Presidential Symposium on Tuesday, December 6.

Oral Abstract Sessions

These sessions include 10-minute didactic presentations of selected abstracts of scientific research in clinical trials, basic and translational research by topics. Experts in the field serve as discussants to place research findings into perspective.

Mini Oral Abstract Sessions

Selected papers will be presented in short 3 – 5 minute presentations in Mini Oral Sessions and then discussed by leading experts who will summarize the finding of those papers including a commentary on the research and outcomes.

Poster Sessions

A large number of abstracts will be selected for Poster presentations. Posters will

be on display in the Exhibit Hall. Presenting Authors of these posters are asked to stand by their posters at a specified time to explain their research and answer questions from delegates.

Young Investigators Session

The Young Investigators
Session, which is designed
specifically for medical
professionals in training and
those in the early stages
of their career, will provide
a unique opportunity to
interact with recognized
leaders in the field of thoracic oncology. The session
will also provide practical,
treatment-oriented, and
career-related information.


Industry Supported Symposia

Industry Supported Symposia will be offered to Conference attendees free of charge. These will be sponsored by a variety of companies. Topics will be chosen after consultation with the Core Program Committee and will compliment the scientific sessions of the Conference.

Exhibit Showcase Sessions


During the morning and afternoon networking as well as the lunch breaks, the Conference will offer Exhibit Showcase Sessions free of charge. These will be sponsored by a variety of companies and take place in the Exhibit Showcase Theater in the Exhibit Hall.

Program at a Glance



TUESDAY DECEMBER 6, 2016

WEDNESDAY DECEMBER 7, 2016



Call for Abstracts

ABSTRACT SUBMISSION OPENS
February 22, 2016

ABSTRACT SUBMISSION DEADLINE July 15, 2016

ABSTRACT DEADLINES

Abstract Submission Opens **February 22, 2016**

Abstract Submission Deadline **July 15, 2016**

Author Notification of Acceptance **September 14, 2016**

Late Breaking Abstract Submission Deadline

October 15, 2016

Presenting Author Registration Deadline **October 21, 2016**

The Core Program and Regional Organizing Committee for the 17th World Conference on Lung Cancer are inviting the submission of scientific abstracts. Authors are asked to submit abstracts under one of the following categories:

- Epidemiology/Tobacco Control & Cessation/Prevention
- Biology/Pathology
- Radiology/Staging/Screening
- Pulmonology
- Early Stage NSCLC
- Locally Advanced NSCLC
- Advanced NSCLC
- SCLC/Neuroendocrine Tumors
- Mesothelioma/Thymic Malignancies/ Esophageal Cancer/Other Thoracic Malignancies
- Surgery
- Radiotherapy
- Chemotherapy/Targeted Therapy/Immunotherapy
- Palliative Care/Ethics
- Trial Design/Statistics
- Regional Aspects/Health Policy/ Public Health
- Scientific Co-operation/Research Groups/Education/Career Development/Young Investigators
- Nurses
- Patient Support & Advocacy Groups



Clinical Trials In Progress

The Conference will also accept submissions of abstracts on Clinical Trials in Progress. Submitters are asked to submit their abstract under the 'Scientific Co-Operating/Research Group' category.

SUBMISSION GUIDELINES

- Research work should be original and innovative. Work can be presented prior to the 17th IASLC WCLC, but MUST include new information/data
- Abstracts must be submitted electronically through the Conference website
- Abstracts will be accepted in English only
- The abstract title must not exceed 125 characters in length
- Abstracts must not exceed 400 words in length (not including title and authors)
- Tables may be included and each will count as 100 words
- A maximum of 2 images may be included; each will count as 100 words
- Abstracts must be structured with the following:
 - Background Methods
 - ResultsConclusion
- The presenting author of an accepted abstract must be registered by October 21, 2016
- There is no fee for submitting an abstract
- There is no limit to the number of co-authors per abstract
- There is no limit to the number of abstracts you may submit (however an individual may not be offered more than 2 oral presentations)
- An international panel of reviewers will review all abstracts anonymously
- All Abstracts accepted by the Scientific Committee will be published in the Journal of Thoracic Oncology (JTO) and the Conference website prior to the meeting and it is mandatory to agree to this at the time of submission
- Financial Disclosure information needs to be completed for EACH co-author at the time of submission through the online abstract submission form; however, information can be provided by the submitting author.

Contact

For any inquiries, please contact wclc2016-abstracts@icsevents.com.

For more information, please visit the IASLC website at **www.iaslc.org**.

LATE-BREAKING ABSTRACT SUBMISSION

In order for an abstract to be considered for Late Breaking Abstract status, the submitting author must submit a place holder abstract before the July 15, deadline. The results and conclusion can be omitted but the type of data that will be presented in the Late-Breaking Abstract must be described as well as why Late-Breaking status is required.

If you wish to apply for late breaking privileges, you must submit an abstract by the regular submission deadline July 15, 2016. To apply for late breaking privileges you must sent an email to wclc2016-abstracts@icsevents.com, indicating your abstract ID number and explaining why data is not yet available and when you expect it to become available. The Core Program Committee will then review your abstract and application. If your application is approved you will be notified and instructed on how to submit your new data by the end of August 2016.

Scholarships

Scholarships are available for Young **Investigators** (35 years of age or younger) and **Developing Nations** (as defined by IASLC) Investigators. These awards will consist of complimentary registration to the Conference, up to four (4) night's accommodation, a fixed amount to cover travel expenses and free membership in the IASLC for one year.

If you fulfill all criteria for both awards, you may apply for both; however, if selected, you will only be offered one award.

Supporting Materials for Young Investigator Award (35 years of age or younger)

- Proof of age
- Curriculum Vitae
- Statement by the senior member (who must be a member of IASLC) of the candidate's role in the research.

Supporting Materials for **Developing Nation Award** (Developing Nation as defined by IASLC)

- Curriculum Vitae
- Description of your interest and current research in lung cancer (1-5 pages)

HOW TO APPLY FOR A SCHOLARSHIP

- The candidate must be the first author and presenter of the submitted abstract
- 2. Abstract must be submitted on or before the submission deadline June 30, 2016 via the online abstract submission form
- Candidate must apply at the time of abstract submission and provide the outlined supporting materials via email to the Conference Secretariat at wclc2016-abstracts@icsevents.com

The deadline for submission of these documents is July 15, 2016.

Application materials received after July 15, 2016 or applications received without supporting materials cannot be considered.

IASLC INTERNATIONAL MENTORSHIP PROGRAM



About the program

The International Mentorship Program is a professional development and education program for early-career physicians/researchers studying thoracic malignancies from economically-developing countries*. The awardees are matched with well-established scientific and clinical mentors from within the hosting WCLC region and visit the mentor's institution for approximately a week following the WCLC.

Goal of the Program

Share information and ideas and teach skills that the awardee can pass along to his or her colleagues at their home intuitions. Establish communication and collaborative relationships between the mentor and mentee, and their respective institutions.

Further information will be available on the Conference website at www.iaslc.org in Spring 2016.

Registration Information



Discounted rates will be available for all IASLC members.

Save up to 100 EUR on registration fees and sign up to become a member of IASLC today!

www.iaslc.org



Contact for Registration

For any inquiries regarding Registration for the 17th IASLC WCLC, please contact wclc2016@icsevents.com.

REGISTRATION OPENS FEBRUARY 22, 2016

Registration fees and further information will be available on the Conference website at **www.iaslc.org** by February 22, 2016.

IASLC CONFERENCE SECRETARIAT & HOUSING BUREAU



17th IASLC World Conference on Lung Cancer c/o International Conference Services Ltd. (ICS)

Suite 2101 – 1177 West Hastings Street Vancouver, BC, Canada V6E 2K3

Phone +16046812153 Fax +16046811049

Email wclc2016@icsevents.com

Accommodation Information

ACCOMMODATION BOOKINGS CAN BE MADE AT THE TIME OF REGISTRATION (Opening February 22, 2016)

The Conference Secretariat (International Conference Services) is the official housing bureau for the 17th IASLC World Conference on Lung Cancer and will offer assistance with the coordination of housing requirements for the Conference. Special room rates have been negotiated and will be available to Conference delegates only.



The success of IASLC and WCLC depends on delegates, sponsors and exhibitors using the official Conference hotels by booking through the official housing bureau.

IASLC/WCLC cannot meet contracted room obligations if registrants reserve rooms outside the official hotel. Rooms that are not filled because of that create an expense for the Association in the form of financial penalties (attrition fees) and place the financial success of the Conference and the Association at risk, which increases with each delegate who stays outside the Conference hotel or books the hotel through channels other than the official housing bureau.



Delegates booking accommodation through the official housing bureau will receive a registration fee discount of up to 100 EUR.

Contact for Housing

For any inquiries regarding Accommodation for the 17th IASLC WCLC, please contact our Housing Team at wclc2016-housing@icsevents.com.

Groups of 10 and More (Registration and/or Housing)

If you have a group of 10 or more, please contact the Group Coordinator at

wclc2016-groups@icsevents.com.



	HOTEL	ADDRESS	STAR RATING	RATES STARTING AT
1	Herrenhof Steigenberger	Herrengasse 10, 1010 Vienna	****	EUR 255
2	Hotel Bristol HQ	Kärntner Ring 1, 1010 Vienna	****	EUR 237
3	Hotel de France	Schottenring 3, 1010 Vienna	****	EUR 240
4	InterContinental Vienna	Johannesgasse 28, 1030 Vienna	****	EUR 223
5	Le Méridien HQ	Opernring 13, 1010 Vienna	****	EUR 255
6	Palais Hansen Kempinski	Schottenring 24, 1010 Vienna	****	EUR305
7	Sofitel Vienna Stephansdom	Praterstraße 1, 1020 Vienna	****	EUR 279
8	The Ritz-Carlton	Schubertring 5, 1010 Vienna	****	EUR 275
9	Vienna Marriott Hotel	Parkring 12A, 1010 Vienna	****	EUR 252
10	25 Hours Hotel at Museumsquartier	Lerchenfelder Straße 1-3, 1070 Vienna	***	EUR 185
11	Arcotel Kaiserwasser	Wagramer Straße 8, 1220 Vienna	****	EUR 179
12	Austria Trend Hotel Astoria	Kärntner Straße 32, 1010 Vienna	****	EUR 180
13	Austria Trend Hotel Europa Wien	Kärntner Straße 18, 1010 Vienna	****	EUR 180
14	Austria Trend Hotel Rathauspark	Rathausstraße 17, 1010 Vienna	****	EUR 136
15	Austria Trend Hotel Savoyen	Rennweg 16, 1030 Vienna	****	EUR 160
16	Courtyard by Marriott Wien Messe	Trabrennstraße 4, 1020 Vienna	***	EUR 255
17	Fleming's Hotel Deluxe Wien City	Josefstädter Straße 10-12, 1080 Vienna	****	EUR 179
18	Fleming's Hotel Wien- Westbahnhof	Neubaugürtel 26-28, 1070 Vienna	****	EUR 142

	HOTEL	ADDRESS	STAR RATING	RATES STARTING AT
19	Hilton Vienna	Am Stadtpark 1, 1030 Vienna	****	EUR 263
20	Hilton Vienna Danube Waterfront	Handelskai 269, 1020 Vienna	****	EUR 242
21	Hilton Vienna Plaza	Schottenring 11, 1010 Vienna	****	EUR 283
22	Hotel Am Konzerthaus - MGallery Collection	Am Heumarkt 35-37, 1030 Vienna	****	EUR 178
23	Hotel Wandl	Petersplatz 9, 1010 Vienna	****	EUR 110
24	Lindner Hotel am Belvedere	Rennweg 12, 1030 Vienna	****	EUR 199
25	Imperial Riding School Renaissance Vienna Hotel	Ungargasse 60, 1030 Vienna	****	EUR 177
26	Mercure Secession	Getreidemarkt 5, 1060 Vienna	****	EUR 176
27	Mercure Wien Zentrum	Fleischmarkt 1a, 1010 Vienna	****	EUR 176
28	Novotel Wien City	Aspernbruecken- gasse 1, 1020 Vienna	****	EUR 176
29	Ibis Wien Mariahilf	Mariahilfer Gürtel 22-24, 1060 Vienna	***	EUR 101
30	Ibis Wien Messe	Lassallestrasse 7a, 1020 Vienna	***	EUR 111
31	Motel One Wien Staatsoper	Elisabethstrasse 5, 1010 Vienna	***	EUR 132
32	Suite Novotel Wien City Donau	Radingerstrasse 2, 1020 Vienna	***	EUR 130
33	Ibis Budget Wien Messe	Lassallestrasse 7, 1020 Vienna	**	EUR 61
34	Motel One Wien Prater	Ausstelungsstraße 40, 1020 Vienna	**	EUR 81
35	Motel One Wien Westbahnhof	Europaplatz 3, 1150 Vienna	**	EUR 81

 $All\,rates\,including\,VAT, service\,charge\,and\,break fast$

Local Information



Vienna, the City of Music

Vienna is the capital of the Republic of Austria, and the largest city in Austria with its population of 1.8 million. It is known as the City of Music, for throughout history a vast majority of great composers and musicians were born and lived in Vienna, leaving behind a great musical legacy. It is also sometimes known as the City of Dreams, as it was home to the world's first psycho-analyst, Sigmund Freud.

Regularly ranked as one of the world's most livable cities, Vienna is an amalgamation of architectural delights and contemporary green living spaces, with more than half of the metropolitan area being made of parks.

Vienna, Facts and Figures

Climate

The month of December is characterized by gradually falling daily high temperatures, with daily highs around 4°C throughout the month

Language

German. English is frequently understood and spoken

Population

1.8 million

Altitude

171 m above sea level

Time Zone

Central European Time, CET

Vienna, the University City

Vienna is the location of 9 Public Universities: University of Vienna (founded in 1365), Medical University of Vienna, Technical University of Vienna, University of Natural Resources and Life Sciences, Vienna University of Economics and Business, University of Veterinary Medicine Vienna, Academy of Fine Arts Vienna, University of Applied Arts Vienna, University of Music and Performing Arts Vienna.

In addition, there are 4 Private Universities: Konservatorium Wien University, Sigmund Freud University Vienna, Webster Vienna Private University, MODUL University Vienna.

Vienna, the Science City

Vienna has a long history of excellent scientific and medical research. Semmelweis, Billroth and Landsteiner are all part of this proud history. The traditions of the Second Vienna Medical School are expressed today in a focus on medical biotechnology focussing on vaccinations, anti-infectives, immunology and oncology. In the 1990s, a vibrant life sciences scene began to develop in Vienna alongside the larger international corporations already

located in the area. A recent study has revealed that Vienna is currently home to 140 life sciences companies.

Vienna, the International City

Vienna hosts one of the four headquarters of the United Nations at the Vienna International Center. Vienna is also the seat of the Organization for Security and Cooperation in Europe (OSCE), the Organization of Petroleum Exporting Countries (OPEC), and many other organizations.

Vienna, the Metropolis of Music

Strike the right note at first-rate concerts and enjoy an unrivalled selection of music —from opera to musical. More famous composers have lived here than in any other city—in Vienna, music is literally in the air: Waltzes and operettas have their home here, and so do musicals "made in Vienna," which have conquered international audiences.

Vienna's Art Treasures

Discover Vienna's rich heritage and the latest achievements in art and architecture—from the magnificent Ringstraße to the trendy MuseumsQuartier, one of the world's ten largest culture complexes.

How to Get There



By Plane

Vienna International Airport

Vienna International Airport is a major airline hub. Over the last decade is has expanded to become one of the fastest growing airports in Europe. Vienna offers a number of major benefits over other airports: an optimal geographic position within Europe, an attractive tariff model for airlines, high punctuality and firstrate service with a minimum transfer time of 25 minutes that is unique in European comparison.



City Airport Train (CAT)

With a journey time of only 16 minutes from Wien-Mitte station to Vienna International Airport, CAT is the fastest means of transport. The CAT travels between Vienna International Airport and Wien-Mitte station every 30 minutes between 06:05 and 23:35. In addition, passengers can already check in their baggage at the City Air Terminal at Wien-Mitte and get their boarding passes at the CITY Air Terminal at Wien-Mitte.

Other Airport Transfers:

- Bus shuttle to city center or Westbahnhof every 20 minutes
- Taxis are available at the airport a few meters after customs clearance. Taxis are safe and cheap. A taxi drive from the airport to the major hotels takes approximately 20-30 minutes.
- Suburban railway S-Bahn to city center every 30 minutes

Bratislava Airport

The M.R. Stefanik Airport Bratislava is the principal international airport of Slovakia, with 24 hours operation. Vienna and Bratislava are the two closest capital cities in the world, with only a short 60 km (40 miles) distance. Numerous trains and buses run daily between Vienna city and Bratislava Airport. The transfer time lies between 75 and 120 minutes depending on traffic and additional stops at the Vienna Airport.



By Railway

Vienna occupies a hub position in Europe's international rail network. Intercity and international express trains like the ICE connect the capital with all parts of Austria and with all major cities in Europe.

The main train station is the newly built Vienna Central Station (Hauptbahnhof) which is within easy reach from all major hotels.



By Motorway

Austria's expressway network extends right into Vienna, making it convenient and safe to reach the city by car or motor coach from anywhere on the European continent.



Public Transportation

Wiener Linien (Metro - Vienna Transport Authority)

- Most modern and efficient network (5 underground lines, 28 tram routes and 84 bus routes, 23 night
- Short waiting times (at peak times between 3 and 5 minutes, in the evening hours between 5 and 15 minutes, night buses operate at half-hourly intervals)
- Operating hours daily from 05:00 to 00:30, night buses from 00:30 to 05:00
- Safe, clean, efficient, easily accessible and offers good value for money



Messe-Prater and Krieau stations service the Messe Wien.

www.wienerlinien.at

PASSPORT, VISA AND BORDER CROSSING INFORMATION

Nationals of countries which signed bilateral or multilateral agreements on the abolition of visa requirement are visa-free if they stay in Austria for a maximum period of 90 days and do not take up employment. Visas are not required for residents of Australia, Canada, and the United States, among others.

For more information, please refer to: www.bmeia.gv.at/en/travel-stay/entry-and-residence-in-austria/entry-and-visa/

OFFICIAL AIRLINE NETWORK

Information regarding the Official Airline Network including discounts for travel to the 17th IASLC World Conference on Lung Cancer will be available on the Conference website.

LETTER OF INVITATION FOR VISA POLICY


An official Letter of Invitation to obtain a Visa and authorization to attend the 17th IASLC World Conference on Lung Cancer will be issued ONLY after registration has been completed and full payment received by the Conference Secretariat. **BANKS AND CURRENCY EXCHANGE**

1 EUR = 1.12 USD

Banks are generally open from 9:00 to 18:00, Monday through Friday. Automatic teller machines (ATMs) are found throughout Vienna. International credit cards are accepted throughout the country at banks, hotels, resorts and the airport. For up-to-date information, please refer to the Universal Currency Converter at: www.

Local Information

U-BAHN (= METRO) STATION MAP



Conference Venue



Messe Wien Exhibition & Congress Center

Messeplatz 1 Postfach 277 A-1021 Vienna Austria

Phone: +43 1727 20-0 www.messecongress.at/en



The 17th IASLC World Conference on Lung Cancer will be held at the Messe Wien Exhibition & Congress Center.

The Messe Wien Exhibition & Congress Center is one of Europe's most attractive and modern exhibition and conference centers. Located in the heart of Vienna, and served by two underground train stations, the Congress Center is easily accessible from the airport, motorway and rail networks. Opened in 2004, its harmoniously designed architecture and innovative hall structure has allowed organizers and visitors alike to produce a stream of wonderful events.

With around 73,000 m² of space, the Congress Center is an ideal venue for planning an international conference.


Unparalleled location

One of the big advantages of the Messe Wien Exhibition & Congress Center is its central location. The venue is served by underground line U2 and the line U1 is very close by as well.

The Center also has excellent links with the airport, the motorway and rail networks.

Just 20 minutes by taxi from Vienna International Airport, it is sandwiched between the Prater park and the nearby Danube.

Notably, the Messe Wien Exhibition & Congress Center is easily within walking distance of the Viennese landmark, the Giant Ferris Wheel, as well as St. Stephen's Cathedral, the Danube River, and a long list of great restaurants for the delegates to try out local Austrian cuisines.



Sponsorship and Exhibit Information



The Conference is pleased to offer a variety of sponsorship options, including but not limited to:

- Industry Supported Symposia
- Exhibit Showcase Sessions
- Hands-On Training Sessions
- Exhibit Space
- Signage Opportunities in and around the Messe Wien Exhibition & Congress Center
- Online and printed advertising opportunities
- Scholarship and Travel Grants
- Virtual and online conference components
- Hotel Key Cards
- many more...

The 17th IASLC World Conference on Lung Cancer offers a tremendous opportunity to market to one of the largest international gatherings of researchers, clinicians and professionals in the field of lung cancer and thoracic oncology. Over 8,000 clinicians and scientists from around the world are expected to attend. Increase your visibility and organization's profile by becoming a Sponsor and/or Exhibitor or by holding an Industry Supported Symposium at this outstanding and important Conference.

For more information regarding sponsorship, symposium and exhibit opportunities, please contact:

Pia Hirsch, International Association for the Study of Lung Cancer (IASLC)

pia.hirsch@iaslc.org

Phone +1720 325 2951 Fax +1720 325 2848

The latest information and updates to this 1st Announcement can be found on the 17th IASLC WCLC website at www.iaslc.org